Outlook Therapeutics: Funding, Investors & Team (Oct 2026)
OVERVIEW Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company. We have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our BioSymphony™ Platform. Oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mAb biosimilars and was designed to provide significant pricing flexibility. PIPELINE Oncobiologics is currently developing a portfolio of eight commercially attractive mAb biosimilars. The company’s most advanced assets, ONS-3010 (a biosimilar of Humira®) and ONS-1045 (a biosimilar of Avastin®) have both successfully completed Phase I trials. We have initiated Phase 3 preparatory activities for ONS-3010 and ONS-1045.` STRATEGY Oncobiologics utilizes its BioSymphony Platform to develop, manufacture and commercialize technically challenging, cost-effective biosimilars on an accelerated timeline and to offer contract development and manufacturing services to development stage biologics companies.
Outlook Therapeutics has raised $30.0M across 2 funding rounds on record, the most recent an undisclosed round of $5.0M announced in Apr 2026.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Outlook Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Outlook Therapeutics Funding Rounds
Outlook Therapeutics raised $25.0M in an undisclosed round announced in Dec 2022.
3.3 years later, an undisclosed round of $5.0M was announced in Apr 2026.
Outlook Therapeutics Founders and Leadership Team
Contact details for the Outlook Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Outlook Therapeutics Funding Compared to Other Biotechnology Startups
Outlook Therapeutics' latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Outlook Therapeutics in Biotechnology and Cranbury
Companies Similar to Outlook Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Outlook Therapeutics Funding FAQs
What does Outlook Therapeutics do?
OVERVIEW Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company. We have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our BioSymphony™ Platform. Oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mAb biosimilars and was designed to provide significant pricing flexibility. PIPELINE Oncobiologics is currently developing a portfolio of eight commercially attractive mAb biosimilars. The company’s most advanced assets, ONS-3010 (a biosimilar of Humira®) and ONS-1045 (a biosimilar of Avastin®) have both successfully completed Phase I trials. We have initiated Phase 3 preparatory activities for ONS-3010 and ONS-1045.` STRATEGY Oncobiologics utilizes its BioSymphony Platform to develop, manufacture and commercialize technically challenging, cost-effective biosimilars on an accelerated timeline and to offer contract development and manufacturing services to development stage biologics companies.
How much funding has Outlook Therapeutics raised?
Outlook Therapeutics has raised $30.0M across 2 rounds on record. The most recent is an undisclosed round of $5.0M announced in Apr 2026.
When did Outlook Therapeutics last raise funding?
Outlook Therapeutics' most recent funding round on record is an undisclosed round of $5.0M, announced in Apr 2026.
Who founded Outlook Therapeutics?
FundedIQ lists Bob Jahr (Founder) at Outlook Therapeutics.
Who is the CEO of Outlook Therapeutics?
C Russell Trenary is listed as CEO at Outlook Therapeutics.
Where is Outlook Therapeutics headquartered?
Outlook Therapeutics is based in Cranbury, New Jersey, United States.
How many employees does Outlook Therapeutics have?
Outlook Therapeutics is in the 101-250 employee band.
How does Outlook Therapeutics' funding compare to other Biotechnology startups?
Outlook Therapeutics' latest round of $5.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Outlook Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Outlook Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.